Immuron business update - ateria health launches juvia™ in australia

Highlights: ateria has launched juvia™ containing breakthrough natural ingredient erme™ in australia new clinical study is underway with the nhs in swansea, wales in people diagnosed with ibs due to malfermentation of carbohydrates in the gut. melbourne, australia, july 11, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that ateria health australia pty ltd, a subsidiary of ateria health limited (“ateria”), has launched juvia™ in australia.
IMRN Ratings Summary
IMRN Quant Ranking